Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Valutazione di SPN-812 (capsule a rilascio prolungato di viloxazina) in bambini in età prescolare con ADHD

2 ottobre 2026 aggiornato da: Supernus Pharmaceuticals, Inc.

Uno studio di fase 4, randomizzato, in doppio cieco, multicentrico, controllato con placebo, a gruppi paralleli sull'efficacia e la sicurezza di SPN-812 nei bambini in età prescolare (dai 4 ai 5 anni) con disturbo da deficit di attenzione/iperattività (ADHD) )

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Panoramica dello studio

Descrizione dettagliata

This is a randomized, double-blind, placebo-controlled, multicenter, 2-arm (1:1), parallel-group, efficacy and safety/tolerability fixed-dose study of SPN-812 in preschool-age children (4 to 5 years old) with ADHD. Participants will be screened for eligibility for up to 4 weeks. Eligible participants will be treated with study medication for 6 weeks. The total duration of the study is up to 10 weeks.

Tipo di studio

Interventistico

Iscrizione (Stimato)

286

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Alabama
      • Saraland, Alabama, Stati Uniti, 36571
    • Arkansas
      • Fayetteville, Arkansas, Stati Uniti, 72703
        • Ritirato
        • Preferred Research Partners-NWA, LLC
      • Little Rock, Arkansas, Stati Uniti, 72211
    • California
      • Anaheim, California, Stati Uniti, 92805
        • Reclutamento
        • Advanced Research Center (ARC), Inc.
        • Contatto:
      • Encino, California, Stati Uniti, 91316
        • Ritirato
        • Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Encino]
      • Garden Grove, California, Stati Uniti, 92844
        • Terminato
        • National Institute of Clinical Research (PICR)
      • Imperial, California, Stati Uniti, 92251
        • Reclutamento
        • Sun Valley Research Center
        • Contatto:
      • Long Beach, California, Stati Uniti, 90807
      • Newport Beach, California, Stati Uniti, 92660
        • Ritirato
        • Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Newport Beach]
    • Colorado
      • Centennial, Colorado, Stati Uniti, 80112
        • Reclutamento
        • IMMUNOe Research Centers
        • Contatto:
        • Contatto:
          • Numero di telefono: 303-773-9000
    • Florida
      • Clermont, Florida, Stati Uniti, 34711
        • Ritirato
        • Vertex Clinical Research, LLC
      • Coral Gables, Florida, Stati Uniti, 33134
        • Reclutamento
        • Luna Research Center
        • Contatto:
          • Numero di telefono: 305-613-7761
      • Gainesville, Florida, Stati Uniti, 32607
        • Terminato
        • Sarkis Clinical Trials
      • Jacksonville, Florida, Stati Uniti, 32256
        • Reclutamento
        • Clinical Neuroscience Solutions, Inc.
        • Contatto:
          • Numero di telefono: 904-281-5757
      • Lakeland, Florida, Stati Uniti, 33803
        • Terminato
        • Accel Research Sites - Lakeland CRU
      • Miami, Florida, Stati Uniti, 33155
      • Orange City, Florida, Stati Uniti, 32763
        • Reclutamento
        • Medical Research Group of Central Florida
        • Contatto:
          • Numero di telefono: 386-775-7627
      • Orlando, Florida, Stati Uniti, 32801
        • Reclutamento
        • Clinical Neuroscience Solutions, Inc.
        • Contatto:
      • Orlando, Florida, Stati Uniti, 32803
        • Reclutamento
        • APG Research LLC
        • Contatto:
        • Contatto:
          • Numero di telefono: 165 407-423-7149
      • Tamarac, Florida, Stati Uniti, 33321
        • Reclutamento
        • D&H Tamarac Research Center
        • Contatto:
      • Virginia Gardens, Florida, Stati Uniti, 33166
      • Winter Park, Florida, Stati Uniti, 32789
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30328
        • Reclutamento
        • Clinical Integrative Research Center of Atlanta
        • Contatto:
          • Numero di telefono: 678-705-7341
      • Atlanta, Georgia, Stati Uniti, 30318
        • Reclutamento
        • Advanced Discovery Research LLC
        • Contatto:
      • Decatur, Georgia, Stati Uniti, 30030
        • Reclutamento
        • CenExcel iResearch, LLC
        • Contatto:
          • Numero di telefono: 404-537-1281
      • Savannah, Georgia, Stati Uniti, 31405
        • Reclutamento
        • CenExel iResearch, LLC.
        • Contatto:
          • Numero di telefono: 912-744-0800
    • Indiana
      • Evansville, Indiana, Stati Uniti, 47715
        • Terminato
        • Qualmedica Research, LLC.
    • Kentucky
      • Bardstown, Kentucky, Stati Uniti, 40004
        • Reclutamento
        • Kentucky Pediatric/Adult Research
        • Contatto:
      • Owensboro, Kentucky, Stati Uniti, 42301
        • Terminato
        • Qualmedica Research, LLC.
    • Louisiana
      • New Orleans, Louisiana, Stati Uniti, 70115
        • Terminato
        • DelRicht Research (Touro Medical Center)
      • Prairieville, Louisiana, Stati Uniti, 70769
        • Reclutamento
        • DelRicht Research
        • Contatto:
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21205
        • Reclutamento
        • Kennedy Krieger Institute
        • Contatto:
          • Numero di telefono: 443-923-3850
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02445
    • Michigan
      • Bloomfield Hills, Michigan, Stati Uniti, 48302
        • Reclutamento
        • Neurobehavioral Medicine Group
        • Contatto:
    • Mississippi
      • Flowood, Mississippi, Stati Uniti, 39232
        • Reclutamento
        • Precise Research Centers
        • Contatto:
          • Numero di telefono: 601-420-5812
    • Nevada
      • Las Vegas, Nevada, Stati Uniti, 89128
        • Reclutamento
        • Clinical Research of Southern Nevada, LLC.
        • Contatto:
    • New Jersey
      • Berlin, New Jersey, Stati Uniti, 08009
        • Ritirato
        • Hassman Research Institute
      • Irvington, New Jersey, Stati Uniti, 07111
      • Neptune City, New Jersey, Stati Uniti, 07753
        • Reclutamento
        • Jersey Shore University Medical Center
        • Contatto:
    • New York
      • New York, New York, Stati Uniti, 10028
        • Ritirato
        • Icahn School of Medicine at Mount Sinai
    • North Carolina
      • Durham, North Carolina, Stati Uniti, 27705
        • Reclutamento
        • Duke University
        • Contatto:
          • Numero di telefono: 919-681-1100
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45229
        • Reclutamento
        • Cincinnati Children's Hospital and Medical Center
        • Contatto:
      • West Chester, Ohio, Stati Uniti, 45069
        • Ritirato
        • CincyScience
    • Oregon
      • Gresham, Oregon, Stati Uniti, 97030
        • Reclutamento
        • Cyn3rgy Research
        • Contatto:
    • Pennsylvania
      • Hershey, Pennsylvania, Stati Uniti, 17033
        • Reclutamento
        • Penn State Health Medical Group - Psychiatry and Behavioral Health
        • Contatto:
        • Contatto:
          • Numero di telefono: 717-531-5656
    • South Carolina
      • North Charleston, South Carolina, Stati Uniti, 29405
      • Summerville, South Carolina, Stati Uniti, 29486
    • Tennessee
      • Memphis, Tennessee, Stati Uniti, 38119
        • Reclutamento
        • Clinical Neuroscience Solutions, Inc.
        • Contatto:
          • Numero di telefono: 901-843-1045
    • Texas
      • Bellaire, Texas, Stati Uniti, 77401
        • Ritirato
        • Houston Clinical Trials, LLC.
      • Dallas, Texas, Stati Uniti, 75230
        • Terminato
        • Javara
      • Plano, Texas, Stati Uniti, 75093
        • Reclutamento
        • AIM Trials, LLC
        • Contatto:
        • Contatto:
          • Numero di telefono: 214-856-2778
      • The Woodlands, Texas, Stati Uniti, 77381
        • Reclutamento
        • Family Psych of The Woodlands
        • Contatto:
    • Virginia
      • Petersburg, Virginia, Stati Uniti, 23805
      • Richmond, Virginia, Stati Uniti, 23220
        • Reclutamento
        • Virginia Commonwealth University, Virginia Treatment Center for Children
        • Contatto:
          • Numero di telefono: 804-628-8736

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 4 anni a 5 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Is male or female 4 years 0 months of age to less than or equal to 5 years 9 months of age at Visit 1 (Screening) and considered medically healthy.
  2. Subject's parent(s) or legal guardian(s)/representative(s) is (are) willing and able to provide written informed consent before completing any study related procedures.
  3. Has a primary diagnosis of ADHD according to DSM-IV-TR criteria and confirmed with the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL).
  4. Has an ADHD-RS-IV-P Total Score of ≥ 28 (males) or ≥ 24 (females) at Visit 1 (Screening) and at Visit 2 (Baseline).
  5. Has a CGI-S score of ≥ 4 (moderate or worse) at Visit 1 (Screening) and at Visit 2 (Baseline).
  6. Has undergone an adequate course of non-pharmacologic treatment or is having symptoms severe enough to warrant pharmacologic treatment without prior non-pharmacologic treatment.
  7. Is participating in a structured group activity (e.g., preschool, kindergarten, sports, Sunday school, summer camp or childcare program) at least 2 days a week during study so as to assess symptoms and impairment in a setting outside the home.
  8. Has not initiated any behavioral intervention/therapy within 30 days of Visit 1 (Screening) and does not plan to initiate any new or discontinue any ongoing behavioral intervention/therapy during the study (e.g., subject is eligible if behavioral intervention/therapy is initiated 30 or more days prior to Visit 1 [Screening] and continues with a similar duration/frequency throughout their study).
  9. Subjects who are on ADHD medication at Visit 1 (Screening), but whose ADHD symptoms are not well controlled on current ADHD medication (e.g., meets Inclusion Criterion #4), meet all other inclusion/exclusion criteria, and discontinues ADHD medication at least 7 days prior to the day of Visit 2 (Baseline) are eligible to participate.
  10. Has no current condition in the opinion of the Investigator that could confound efficacy assessments, safety assessments or increase participant risk.
  11. Has lived with the same parent(s) or legal guardian(s) or has lived under a shared living arrangement (e.g., joint legal custody) for greater than or equal to 6 months prior to Visit 1 (Screening).
  12. Has a body weight ≥5th percentile for age and sex at Visit 1 (Screening) and Visit 2 (Baseline).

Exclusion Criteria:

  1. Has a diagnosis at Screening (per K-SADS-PL) of another psychiatric disorder that is considered to be the primary diagnosis rather than ADHD or has a comorbid psychiatric disorder secondary to ADHD that, in the opinion of the investigator (after consulting medical monitor), will likely interfere with study treatment adherence and/or impact study results.
  2. Has a current diagnosis of a major neurological disorder. The eligibility of those who have seizures, a history of seizure-like events (e.g., syncope, myoclonus, severe muscle spasms), a family history of seizure disorder (immediate family, i.e., sibling, parent), and/or febrile seizures will be assessed on a case-by-case basis after consulting the medical monitor.
  3. History of Bipolar Disorder diagnosed in a first degree relative.
  4. Has global development delay or intellectual disability by medical history.
  5. Has a current diagnosis of a significant (per Investigator's evaluation and/or judgement) systemic disease.
  6. Has body mass index > 95th percentile for the subject's age and sex at Visit 1 (Screening) or Visit 2 (Baseline).
  7. Has a mean resting systolic and diastolic blood pressure* that are both >95th percentile for age sex, and height and has a mean resting pulse rate* that is >95th percentile for age and sex (males: >117 bpm; females: >122 bpm) at Visit 1 (Screening) or Visit 2 (Baseline). * Note: The mean of three measurements while seated.
  8. Has a clinically significant electrocardiogram finding(s) at Visit 1 (Screening).
  9. Is currently taking SPN-812 for ADHD, has previously taken SPN-812 for ADHD, but discontinued due to a lack of efficacy or adverse reactions, or has history of allergic reaction, hypersensitivity or intolerance to viloxazine.
  10. Has an allergy to or cannot swallow pudding and applesauce and cannot swallow intact capsule whole.
  11. Has any food allergy, intolerance, restriction or special diet that, in the opinion of the Investigator, could contraindicate the subject's participation in the study.
  12. Has received any investigational drug within the longer of 30 days or 5 half-lives prior to Visit 2 (e.g., first dose of study medication).
  13. Has a positive urine drug test at Visit 1 (Screening). A positive test for amphetamines is allowed for subjects receiving a stimulant ADHD medication at Screening. The subject will be required to discontinue the stimulant for the duration of the study, beginning at least 7 days prior to Visit 2 (Baseline).
  14. Is using of prohibited concomitant medications including known CYP1A2 substrates (e.g., theophylline, melatonin) during the Screening Period or (anticipated) for the duration of the study.
  15. Any reason that, in the opinion of the Investigator, would prevent the subject from participating in the study.
  16. Has suicidal ideation ("Yes" indicated on C-SSRS question 4 or 5) or suicidal behavior ("Yes" indicated on C-SSRS for any suicidal behavior) within 6 months prior to or the day of Visit 1 (Screening) or has attempted suicide ("Yes" indicated on C-SSRS for lifetime).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Placebo

Placebo, qd

Placebo will be administered once daily

Sperimentale: SPN-812

SPN-812, qd

100mg SPN-812 will be administered once daily and compared to Placebo

Altri nomi:
  • SPN-812

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change from Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Total Score at End of Study (Week 6)
Lasso di tempo: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I", 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the ratings of all 18 items yields the raw Total score (range: 0-54; the higher the Total score, the more severe the ADHD symptoms). Post-baseline raw Total scores are converted to a change from baseline Total score. A lower change from baseline ADHD-RS-IV-P Total Score (<0) represents a better outcome.

Baseline and Week 6

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change from Baseline in the Clinical Global Impression of Severity (CGI-S) Score at End of Study (Week 6)
Lasso di tempo: Baseline and Week 6

The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients (the higher the score, the more severe the overall ADHD symptoms). Post-baseline (raw) CGI-S scores are converted to a change from baseline score. A lower change from baseline CGI-S score (<0) represents a better outcome.

Baseline and Week 6
Clinical Global Impression of Change (CGI-C) Score at End of Study (Week 6)
Lasso di tempo: Week 6

The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". A CGI-C score <4 represents a better outcome.

Week 6
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Hyperactivity/Impulsivity Subscale Score at End of Study (Week 6)
Lasso di tempo: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine H/I items yields the raw H/I subscale score (range: 0-27; the higher the H/I subscale score, the more severe the H/I symptoms). Post-baseline raw H/I subscale scores are converted to a change from baseline score. A lower change from baseline H/I subscale score (<0) represents a better outcome.

Baseline and Week 6
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Inattention Subscale Score at End of Study (Week 6)
Lasso di tempo: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine IA items yields the raw IA subscale score (range: 0-27; the higher the IA subscale score, the more severe the IA symptoms). Post-baseline raw IA subscale scores are converted to a change from baseline score. A lower change from baseline IA subscale score (<0) represents a better outcome.

Baseline and Week 6
Clinical Global Impression of Severity (CGI-S) Responder Rate (percentage of subjects with CGI-S score of 1 or 2) at End of Study (Week 6)
Lasso di tempo: Baseline and Week 6

The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients. The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders".

Baseline and Week 6
Clinical Global Impression of Change (CGI-C) Responder Rate (percentage of subjects with CGI-C score of 1 or 2) at End of Study (Week 6)
Lasso di tempo: Week 6

The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders".

Week 6
Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Responder Rate (percentage of subjects with ≥ 50% Reduction in Change from Baseline) at End of Study (Week 6)
Lasso di tempo: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two 9 item subscales: inattention and hyperactivity-impulsivity. The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale; 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. Sum of 18 ratings yields the Total score (range: 0-54; higher score represents severer symptoms). Percent reduction is calculated for the ADHD-RS-IV-P score: [("Post-baseline"-"Baseline")/"Baseline"] x 100; range: 0 to 100%; a "responder" is a subject with a 50% or greater reduction in change from baseline Total score. Responder rate (percent of responders) is calculated: ["number of 'responders' (m)"/ "number of subjects analyzed" (n)] X 100; range: 0 to 100%. A Responder Rate greater than 50%, represents more "responders" versus "nonresponders".

Baseline and Week 6

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Joseph Hull, PhD, Supernus Pharmaceuticals, Inc.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

19 marzo 2024

Completamento primario (Stimato)

1 gennaio 2028

Completamento dello studio (Stimato)

1 gennaio 2028

Date di iscrizione allo studio

Primo inviato

26 febbraio 2021

Primo inviato che soddisfa i criteri di controllo qualità

1 marzo 2021

Primo Inserito (Effettivo)

4 marzo 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • 812P401

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi